Aberrant AKT activation drives well-differentiated liposarcoma

Area of Science:

• Oncology
• Zebrafish models
• Molecular pathology

Background:

• Well-differentiated liposarcoma (WDLPS) is a common human sarcoma resistant to conventional therapies.
• Limited animal models hinder research into WDLPS pathobiology and targeted therapy development.

Purpose of the Study:

• To develop a novel animal model for studying WDLPS.
• To investigate the role of Akt signaling in WDLPS pathogenesis.
• To identify potential therapeutic targets for WDLPS.

Main Methods:

• Zebrafish engineered to express constitutively active Akt2 in mesenchymal progenitors.
• Analysis of tumor incidence in zebrafish with varying p53 gene status.
• Immunohistochemistry and Western blot analysis of human WDLPS/DDLPS specimens and cell lines.
• Treatment of WDLPS/DDLPS cell lines with BEZ235, a PI3K/mTOR inhibitor.

Main Results:

• Zebrafish Akt2 activation successfully models human WDLPS.
• Aberrant Akt activation cooperates with p53 mutations to promote WDLPS.
• AKT activation is detected in a subset of human WDLPS/DDLPS cases and cell lines.
• The PI3K/mTOR inhibitor BEZ235 effectively reduces WDLPS/DDLPS cell viability.

Conclusions:

• A zebrafish model provides new insights into WDLPS molecular pathogenesis.
• AKT signaling is implicated as a key driver in WDLPS.
• Targeting AKT represents a promising therapeutic strategy for chemoresistant liposarcoma.